•
Lead and Disrupt
Talks about Innovation, Corporate Innovation and Disruption
SW
Steve Weinstein
Venture Investor
Greater Boston
Overview
Steve Weinstein is a Venture Investor and CEO in the life science industry with notable experience at companies like Novartis and Genentech. He has successfully invested in various companies at different stages, including Syndicate at Seed stage and ROX Medical at Series E, showcasing his expertise in venture capital and strategic planning.
Work Experience
Managing Member
2018 - Current
• Consulting and advisory to medtech, biotech and digital health start-ups.
Chairman
2019
• Next generation intravascular cardiology imaging combining DeepOCT™ imaging, near infrared spectroscopy (NIRS), and AI-powered insights to optimize coronary stenting and better inform care.
Spectrawave is a medical device company that develops optical diagnostic and therapeutic devices.
Raised $79,597,066.00 from Deerfield Management, Nova Ventures, Johnson & Johnson Innovation – JJDC, Heartwork Capital, S3 Ventures, SV Health Investors and Lumira Ventures.
Strategic Advisor
2019
• Clinical research and commercial translation strategy related to mental health, neuomodulation, addiction, and digital tools in clinical practice.
Product Development Review Council Member
2018
Council reviews oncology-focused grants of up to $20M/company.
Cancer Prevention and Research Institute of Texas is a state agency that invests in cancer prevention and academic research.
Raised $2,000,000.00.
Board Member
2021
CEO
2021 - 2023
• Joined as Independent Director. Became Interim CEO to build senior leadership team including CSO, CMO, and Data Science. Developed new R&D and clinical strategy. • Development stage prostate cancer prognostic for monitoring patients with low risk tumors (Active Surveillance)
Gregor Diagnostics is a molecular diagnostics company developing a screening test technology for prostate cancer.
Raised $6,885,377.00 from First Round Capital and Green Park & Golf Ventures.
Board Member
2021
Developing an ingestible drug/device which detects and reverses opioid overdose.
Celero Systems is a life sciences company that develops an ingestible system to detect and reverse opioid overdose.
Raised $3,000,000.00 from PharmStars.
Consultant, Neuroscience Innovation
2021 - 2024
• Developed best practices recommendations for corporate innovation. • Evaluate technologies and manage projects that transform the treatment of neurological diseases including neuromuscular, precision psychiatry, and drug delivery.
Genentech specializes in genetic testing and personalized medicine.
Interim COO
2019 - 2020
• Non-Profit Microbiome Research Institute; Collect process, and commercial FMT for CDiff. • Oversaw clinical research (IIT studies), finance, regulatory, and operations.
OpenBiome is a nonprofit organization dedicated to expanding safe access to fecal microbiota transplants (FMT), and to catalyzing research.
Raised $125,000.00 from The Draper Richards Kaplan Foundation.
Interim CEO and Board Member
2018 - 2019
Clinical stage hypertension medical device.
Managing Director, Novartis Venture Fund
2006 - 2018
• Managed $800M global portfolio as one of eight Managing Directors (four US MDs). Led Medtech portfolio. • Investment partner for all investment decisions across the fund globally. Mentored junior colleagues. • Sourced and invested across all therapeutic areas and modalities, including medical device, biotech, and digital. • Invested across all stages including company formation, preclinical, clinical, and commercial. • Led scientific, clinical, and financial diligence, and structured investments as lead investor. • Built syndicates up to $45M, with NVF investment up to $25M over the life of a company. • Played an integral role in portfolio company oversight: executive recruitment, clinical/commercial strategy, governance, financing events, and exit/acquisition business development and negotiation. • Developed fund best practices, related to diligence, portfolio management, and fund cash flow management. • Representative Board of Directors and portfolio engagement: Ablation Frontiers (cardiac Afib, acquired Medtronic), Autonomic Technologies (neuromodulation), Cavion (essential tremor, Acquired Jazz), Celladon (heart failure, IPO), Innocrin (oncology), Sonitus (hearing), Symetis (cardiovascular, acquired Boston Scientific), Viamet (antifungal/women’s health, acquired Novaquest), Visiogen (ophthalmology, acquired Abbott). • Recruited Entrepreneur-In-Residence and evaluated NewCo development in ophthalmology. Clinical areas including: anti-infectives, cardiology, diabetes, diagnostics, immunology, otology, ophthalmology, oncology, respiratory, and neuroscience.
Education
Investments
Latest Articles
•
Why Innovation Heroes are a Sign of a Dysfunctional Organization
Talks about Innovation, Disruptive Innovation and Corporate Innovation
•
The Class That Changed The Way Entrepreneurship Is Taught
Talks about Teaching, Higher Education and Lean Startup
•
Lean LaunchPad — For Deep Science and Technology
Talks about Technology, Lean Startup and Teaching